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Abstract
Focal nodular hyperplasia (FNH) and hepatocellular adeno-
mas (HCAs) constitute benign hepatic neoplasms in adults.
HCAs are monoclonal neoplasms characterised by an in-
creased predilection to haemorrhage and also malignant trans-
formation. On the other hand, FNH is a polyclonal tumour-
like lesion that occurs in response to increased perfusion and
has an uneventful clinical course. Recent advances in molec-
ular genetics and genotype-phenotype correlation in these he-
patocellular neoplasms have enabled a new classification sys-
tem. FNHs are classified into the typical and atypical types
based on histomorphological and imaging features. HCAs
have been categorised into four subtypes: (1) HCAs with
HNF-1αmutations are diffusely steatotic, do not undergo ma-
lignant transformation, and are associated with familial diabe-
tes or adenomatosis. (2) Inflammatory HCAs are
hypervascular with marked peliosis and a tendency to bleed.
They are associated with obesity, alcohol and hepatic
steatosis. (3) HCAs with β-catenin mutations are associated
with male hormone administration and glycogen storage dis-
ease, frequently undergo malignant transformation and may
simulate hepatocellular carcinoma on imaging. (4) The final
type is unclassified HCAs. Each of these except the unclassi-
fied subtype has a few distinct imaging features, often en-
abling reasonably accurate diagnosis. Biopsy with immuno-
histochemical analysis is helpful in difficult cases and has
strong implications for patient management.
Teaching points
• FNHs are benign polyclonal neoplasms with no risk of
haemorrhage or malignancy.
• HCAs are benign monoclonal neoplasms classified into four
subtypes based on immunohistochemistry.
• Inflammatory HCAs show an atoll sign with a risk of bleed-
ing and malignant transformation.
• HNF-1α HCAs are steatotic HCAs with minimal complica-
tions and the best prognosis.
• β-Catenin HCA shows variable MRI features and a high risk
of malignancy.
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Introduction
Benign hepatocellular lesions in adults can be divided into
two main categories according to their pathogenesis: regener-
ative lesions, composed mainly of focal nodular hyperplasia
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(FNH), and neoplastic lesions, corresponding to hepatocellu-
lar adenomas (HCAs) [1]. FNH and HCAs are the second and
third most common benign liver tumours after haemangiomas,
respectively [1, 2]. Accurate imaging differentiation of these
two types of lesions is essential as the treatment strategies
differ considerably. HCAs can present with bleeding or under-
go malignant degeneration and often require surgery whereas
FNH is a do-not-touch lesion. The recent identification of
various molecular pathways altered in these tumours has sig-
nificantly increased our knowledge of benign hepatocellular
tumorigenesis. Moreover, knowledge of the genotype-
phenotype correlation in HCA has helped in establishing a
new radio-pathological classification. New immunohisto-
chemical and cytogenetic markers have been identified for
differentiating various subtypes of HCA. Various studies have
identified specific imaging features corresponding to typical
and atypical FNH and for differentiating various subtypes of
HCA. In this review, we focus on the recent progress in the
understanding of the molecular mechanisms and characteristic
cross-sectional imaging features with special emphasis on the
role of MRI in these two hepatocellular tumours. We also
discuss their role in deciding on the different management
strategies after diagnosis.
Focal nodular hyperplasia (FNH)
FNH is defined as a nodule composed of benign-appearing
hepatocytes occurring in a liver that is otherwise histologically
normal or nearly normal. It is the second most common be-
nign liver tumour after haemangioma with a prevalence of
0.9 % and commonly occurs in young females (male:female
ratio=1:8) [3]. The majority of FNHs are solitary (80 %),
smaller than 5 cm in diameter and occur near the surface of
the liver [4]. In contrast to monoclonal HCAs, which frequent-
ly bleed, FNHs are polyclonal tumour-like lesions and do not
undergo haemorrhage or malignant transformation [5]. Al-
though an association with oral contraceptive use has been
speculated, owing to the increased prevalence of these tu-
mours in young women, studies have shown that FNH is not
hormonally dependent [6]. Association with vascular diseases
such as hereditary haemorrhagic telangiectasia (Rendu-Osler-
Weber disease) and congenital absence of the portal vein can
be seen [1].
FNH is often an incidental finding at imaging. Distinction
between FNH and other hypervascular liver lesions such as
HCA, hepatocellular carcinoma (HCC) and hypervascular
metastases is critical as the management differs considerably.
FNH is asymptomatic in most patients, and in such cases no
treatment is necessary. One third of patients may present with
abdominal pain or a palpable mass. Typically, FNH follows a
benign natural course and remains stable or may even de-
crease in size at follow-up examination [5].
Molecular cytogenetics and pathogenesis
Genetic analysis of FNH failed to identify somatic gene mu-
tations in the β-catenin gene (CTNNB1), TP53, APC or
HNF1α. FNH typically shows dysregulation of the
angiopoietin genes, which are responsible for the maturation
of blood vessels. An increase in the angiopoietin expression
results in uncontrolled maturation and remodelling of vessels,
resulting in dystrophic vascular architecture typical of FNH
[1, 7]. Wanless et al. postulated that portal tract injury due to
either portal tract inflammation or arterial ischaemia is the
primary event leading to vascular shunting with hepatocyte
hyperplasia and cholestasis [8, 9]. Arterial hyperperfusion
and the resultant hyperoxemia lead to increased expression
of vascular endothelial and somatic growth factors and acti-
vation of hepatic stellate cells leading to the formation of the
characteristic central scar [8].
The β-catenin pathway is activated, including the down-
stream target, glutamine synthetase, which explains the poly-
clonal over-proliferation of hepatocytes. The molecular mech-
anisms of this activation are uncertain, but do not involve
demonstrable mutations in β-catenin or Axin, unlike HCA
[10]. Immunohistochemistry shows a perivenous map-like
distribution of glutamine synthetase [11].
Classification
Currently, FNH is divided into two types: classic and non-
classic or atypical. [12].
Classic FNH
Classic FNH is characterised by the presence of abnormal
nodular architecture, malformed vessels and cholangiolar pro-
liferation. One or more macroscopic central scars are present
in most cases that contain fibrous connective tissue,
cholangiolar proliferation with surrounding inflammatory in-
filtrates and malformed vessels. Arterial blood flows centrifu-
gally from the anomalous central arteries. Approximately
50 % of lesions show some degree of fatty infiltration, as
opposed to the surrounding liver, which shows signs of
steatosis in less than 20 % of lesions. Both the classic and
non-classic types contain variable amounts of Kupffer cells
[13].
Imaging features
Classic FNH has typical imaging findings enabling accurate
diagnosis. FNH is found as an incidental iso- to hypoechoic
focal lesion on ultrasound although the isoechoic nature often
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makes the detection of lesions difficult. A central vascular scar
may be seen. Further evaluation with dynamic contrast-
enhanced CTor MRI is warranted in most cases for definitive
diagnosis. It appears as a lobulated iso- to hypodense lesion on
unenhanced CT and shows homogeneous, intense arterial en-
hancement becoming isoattenuating in the portal and delayed
phases with no washout. The central scar showing delayed
enhancement because of myxomatous stroma can be seen in
20 % of cases [14].
Magnetic resonance imaging (MRI) has higher sensitivity
(70 %) and specificity (98 %) for FNH than US and CT. MRI
features include T1 iso- or hypointensity (94–100 %), T2
slight hyper- or isointensity (94–100 %) and a hyperintense
central scar (84 %). A scar is usually seen in FNH>3 cm [15].
Lesions show intense homogeneous enhancement in the arte-
rial phase, isointensity during the portal phase and delayed
enhancement of the central scar [16] (Fig. 1).
Hepatobiliary-specific contrast agents are being increasing-
ly used in differentiating focal liver lesions. FNH is
characterised by an increased density of functioning hepato-
cytes and hence shows persistent enhancement (iso- or
hyperintense) on delayed phase (20 min) gadoxetic acid-
enhanced images (Fig. 2). Three patterns of enhancement
are described on the 20-min hepatobiliary phase: a homoge-
neously hyperintense, inhomogeneously hyperintense and pe-
ripheral hyperintense rim (hypointense with a ring pattern)
(Fig. 3). Approximately 10–12 % of the lesions may not show
hyperintensity on the 20-min delayed phase, warranting fur-
ther evaluation with biopsy or close interval imaging [17]. The
presence of abnormal bile ductules that fail to communicate
with the normal biliary system possibly results in defective or
delayed excretion with persistent contrast agent retention [18,
19]. In contrast, HCA and HCC typically do not show contrast
agent retention. A central scar appears hypointense on 10- and
20-min delayed phases because of the predominant fibrous
tissue with no well-formed bile ductules [20, 21].
Non-classic FNH
Non-classic FNH lesions always show cholangiolar prolifera-
tion like classic FNH but lack either nodular abnormal archi-
tecture or malformed vessels. Lack of a central scar, incom-
plete multinodular organisation and prominent areas of con-
gestion are some of the histopathological features of non-
classic or atypical FNH [22, 12].
Imaging features
Typical MRI features of FNH lesions, which include homo-
geneous iso- to hypointensity on TI-weighted images, homo-
geneous slight hyper- to isointensity on T2-weighted images
and a central hyperintense scar on T2-weighted images, are
seen in only 9–50% of these lesions [23, 24]. Various atypical
features described at MRI include [16, 25, 26]:
1. Heterogeneous signal intensity on both T1- and T2
weighted sequences due to sinusoidal dilatation, fatty in-
filtration and/or small haemorrhagic foci.
Fig. 1 Classic focal nodular hyperplasia (FNH) in a 40-year-old female
incidentally detected on ultrasound (not shown here). (a) Axial T2WMRI
shows a well-circumscribed T2 isointense lesion (long arrow) in the left
lobe of the liver with a central T2 hyperintense scar (short arrow). (b)
Axial T1W MRI shows a well-circumscribed T1 isointense lesion (long
arrow) in the left lobe of the liver with a central T2 hypointense scar (short
arrow). (c) Axial post-contrast MRI in the arterial phase reveals intense
enhancement of the lesion (long arrow) with a non-enhancing central scar
(short arrow). Axial post-contrast MRI in the venous (d) and delayed
phases (e and f) shows the isointense nature of the lesion (long arrow)
with progressive delayed enhancement of the central scar (short arrow)
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2. T1 hyperintensity due to fat, copper accumulation, high
protein concentrations, blood degradation products or si-
nusoidal dilatation.
3. Absense of a central scar, which is typically detectable for
lesions greater than 3 cm. The scar can be extremely small
or undetectable on CT (16–40 %) and MRI (22 %) [4, 14,
Fig. 2 Classic FNH in a 35-year-old female with hepatobiliary-specific
contrast (gadoxetate). (a) Axial T2W MRI shows two large isointense
lesions in the left lobe of the liver (short arrows) with a T2 hyperintense
central scar (long arrow). (b) Axial T1WMRI shows two large isointense
lesions in the left lobe of the liver (short arrows) with a T1 hypointense
central scar (long arrow). Axial post-contrastMRIwith gadoxetate shows
intense enhancement of the lesions (short arrows) in the arterial phase (c)
becoming isointense on the portal venous phase (d) and persistent en-
hancement in the 20-min hepatobiliary phase (e). The central scar shows
no enhancement (long arrow)
Fig. 3 Appearance of FNH with hepatobiliary-specific contrast
(gadoxetate) and a routine extracellular agent (gadolinium). (a) Axial
T2W MRI shows iso- to mildly hyperintense lesions in segment 4 of
the left lobe of the liver (arrow). (b) Axial post-contrast MRI with
gadoxetate shows intense enhancement of the lesions in the arterial phase
with a non-enhancing central scar (arrow). (c) Axial post-contrast MRI in
the 20-min hepatobiliary phase shows a peripheral ring of hyperintensity
(arrow) with central non-enhancement (asterisk). Follow-up MRI with
gadolinium after 6 months shows an enhancing lesion with a non-
enhancing scar (arrow) in the arterial phase (d) and persistent enhance-
ment in the portal venous (e) and delayed phases (f) with delayed en-
hancement of the central scar (arrow)
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27]. The central scar can appear hypointense on T2 with
no delayed enhancement mimicking the collagenous scar
seen in HCA, fibro-lamellar carcinoma, HCC or
intrahepatic cholangiocarcinoma likely from obliterative
vascular hyperplasia of the central scar [4, 15].
4. A pseudo-capsule due to compressive effects on the adja-
cent hepatic parenchyma as well as the presence of dilated
vessels and sinusoids around the lesion.
5. Interval growth is considered an atypical and worrisome
finding in FNH.
6. FNH can rarely show intralesional steatosis, often due to
extension from the underlying hepatic steatosis (Fig. 4).
Other possible explanations for intralesional steatosis in
FNH are hepatic injury associated with steatosis from al-
coholic toxicity, obesity, diabetes or malnutrition [28, 29].
7. Telangiectatic FNH is an uncommon entity but the most
common among non-classic FNHs. These lesions often
show heterogeneity on pre- and post-contrast CT and
MRI, and they are strongly hyperintense on T1- and T2-
weighted images, often with an absent central scar. In-
tense arterial enhancement with persistent enhancement
during the hepatic venous and equilibrium phases is seen.
Recently, a molecular study identified several genetic sim-
ilarities between telangiectatic FNH and HCA indicating
most of these are actually inflammatory hepatic adenomas
and have been misclassified as 'telangiectatic FNH' [30].
8. Development of FNH in childhood and presence of symp-
toms can also be considered as atypical features.
9. Approximately 20 % of patients have multiple FNHs,
which are often of a non-classic subtype with atypical
imaging features. Multiple FNH syndrome is defined as
consisting of two or more FNHs in combination with
hepatic liver haemangioma or vascular malformations or
intracranial tumours [31, 32] (Fig. 5). Focal disturbance of
the hepatic blood supply has been advocated as the most
likely causative factor for the concomitant development
of these benign hepatic lesions.
Management
FNHwith typical imaging features is managed conservatively
and does not necessitate surgical intervention. Surgical exci-
sion is considered for symptomatic lesions likely from com-
pression of adjacent structures or hepatic capsular stretching.
FNH with atypical imaging features needs further evaluation
in the form of additional imaging, percutaneous guided biopsy
and follow-up. Suspicious lesions could be followed up or
surgically excised [33].
Hepatocellular adenoma (HCA)
HCAs are rare benign monoclonal hepatic tumours that com-
monly occur in females who have been receiving oral contra-
ceptives. The duration of oral contraceptive use and oestrogen
content determine the risk of developing HCA. It rarely occurs
in children and men (male:female=1:9) [34]. Other risk fac-
tors for HCAs include use of anabolic steroids, glycogen stor-
age disease (types Ia, III and VI), haemochromatosis, andro-
gen therapy, and use of barbiturates and clomiphene [35].
Fig. 4 Biopsy-proven FNH with intralesional steatosis in a 46-year-old
female. (a) Axial T2W MRI shows an isointense lesion (long arrow) in
the left lobe of the liver with a faint hyperintense central scar (short
arrow). Axial T1 in-phase (b) and out-of-phase (c) MRIs show a drop
in signal in the out-of-phase images representing intralesional lipid
(arrow). Axial post-contrast MRI shows an enhancing lesion (arrow) in
the arterial phase (d) becoming iso- to mildly hypointense in the portal
venous (e) and delayed phases (f) with delayed enhancement of the cen-
tral scar (arrow). Arrowheads denote transient oedema/enhancement
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Patients may present with right upper quadrant pain or a pal-
pable mass. Up to 50 % of patients are asymptomatic. HCAs
can be complicated by life-threatening bleeding or undergo
malignant transformation necessitating surgical management
[36].
Classification
Initially three MRI patterns were identified corresponding to
three pathologic forms, namely the steatotic, peliotic and
mixed types [37]. Later, the Bordeaux group divided HCAs
into four different subgroups based on molecular genetics,
histopathology and clinical features. Various studies have de-
scribed characteristic imaging features enabling precise diag-
nosis in select subtypes. Accordingly, HCAs are currently
categorised into four distinct genetic and pathologic subtypes:
(1) inflammatory HCAs, (2) hepatocyte nuclear factor 1 alpha
(HNF-1α)-mutated HCAs, (3) β-catenin-mutated HCAs and
(4) unclassified [38, 39].
Inflammatory HCAs
Inflammatory HCAs are the most common subtype and ac-
count for about 40–50 % of all HCAs. Inflammatory HCAs
include liver tumours previously referred to as Btelangiectatic
FNH^ or Btelangiectatic adenomas^. They occur most fre-
quently in young females with a history of oral contraceptive
usage and in obese patients. Patients may present with signs of
chronic anaemia and/or systemic inflammatory syndrome
characterised by fever, leukocytosis and elevated serum C-
reactive protein [40].
Sustained activation of the Janus kinase (JAK)-signal trans-
ducer and activator of transcription (STAT) pathway (JAK-
STAT pathway), with resultant hepatocellular proliferation,
is the proposed pathogenesis in the development of inflamma-
tory HCAs. This can happen via two pathways: (1) somatic
gain-of-function mutations involving the IL6ST gene, which
encodes the oncogene gp130 in 60 % of cases, and (2) STAT3
activation without mutations in gp130 in 40 % of cases [38].
Often there is activation of acute-phase inflammation proteins,
such as serum amyloid A and C-reactive protein [11].
Inflammatory HCAs appear heterogeneous with areas of
congestion and frank haemorrhage on gross pathology. In-
tense polymorph nuclear infiltrates, marked sinusoidal dilata-
tion and thick-walled arteries are seen on histopathology. Im-
munohistochemistry shows homogeneous glutamine synthe-
tase and β-catenin staining [11].
On imaging, inflammatory HCAsmanifest as hypervascular
liver masses with persistent enhancement on portal venous and
delayed phase images. They show diffuse T2 hyperintensity
and iso- to mild T1 hyperintensity. Focal areas of microscopic
fat may be seen in a small (11 %) subset of patients. Sensitivity,
specificity, positive and negative predictive values of marked
T2 hyperintense signal with delayed persistent enhancement
are 85.2, 87.5, and 88.5 and 84 %, respectively, for the diagno-
sis of inflammatory HCAs [41]. The atoll sign, present in ap-
proximately 50 % of cases, includes a T2 hyperintense rim in
the periphery of the lesion (correlating with dilated sinusoids)
with central isointensity resembling a coral reef and lagoon
Fig. 5 Multiple FNH syndrome in a 50-year-old female. (a) Axial T2W
MRI shows two iso- to mildly hyperintense focal lesions (arrows) in
segments 8 and 4 of the liver. Axial post-contrast MRI shows intense
enhancement of the lesions (arrow) in the arterial phase (b) and persistent
enhancement (arrow) in the portal venous (c) and delayed phases (d) with
delayed enhancement of the central scar (arrowheads). (e) Axial T2W
MRI in the same patient shows a small T2 hyperintense lesion in segment
7 (arrow). Axial post-contrast MRI shows peripheral nodular enhance-
ment (arrow) in the arterial phase (f) with progressive centripetal filling
(arrow) in delayed phase (g) in keeping with haemangioma. (h) Axial
post-contrast MRI brain shows a small enhancing extra-axial lesion in the
falx cerebri representing meningioma
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respectively (Figs. 6 and 7). Small intralesional T2-
hyperintense nodules can be found in the centre of the lesion
(small islands) [42].
HNF-1α-mutated HCAs
HNF-1α-mutated HCAs are the second most common subtype
and constitute 30–35 % of all HCAs. These develop exclusive-
ly in female patients with a history of oral contraceptive use and
the tumours are multiple in about 50 % of patients. Often these
are incidentally discovered on CT performed for other reasons
and are asymptomatic. An association with maturity-onset dia-
betes of the young (MODY), type 3 and familial hepatic
adenomatosis has been reported [36, 43, 44].
Biallelic-inactivatingmutation of the TCF1 gene inactivating
hepatocyte nuclear factor 1α (HNF-1 α) is the primary event
and could be somatic (90–95 %) or germ line (up to 10 %) in
origin. The resultant non-functioningHNF-1α protein promotes
lipogenesis and hepatocellular proliferation. Also there is sup-
pression of liver fatty acid-binding protein, resulting in impaired
fatty acid transport in hepatocytes, leading to intracellular fat
deposition. Oestrogens act as endogenous genotoxic agents
and cause hepatocyte proliferation by somatic mutations in the
TCF1 gene [2, 36, 38].
Excessive lipid accumulation in the tumour hepatocytes is
typical on histopathology. No portal tract elements or
cytological abnormalities are seen. Immunohistochemistry
shows characteristic absence of liver fatty acid-binding pro-
tein [11].
On MRI, these tumours show predominantly hyper- or
isointensity on T1 with a diffuse signal drop on chemical shift
imaging (CSI) because of intracellular steatosis. T1
hyperintensity could also be due to glycogen and haemorrhage.
Iso- to slight hyperintensity is seen on T2. Moderate enhance-
ment in the arterial phase with no persistent enhancement in the
portal venous and delayed phases is typical (Fig. 8). Sensitivity,
specificity, and positive and negative predictive values of a ho-
mogeneous signal drop on CSI for the diagnosis of HNF-1α-
mutated HCAs are 86.7, 100, 100 and 94.7 %, respectively [41].
Uncommonly macroscopic fat could be identified on CT in ap-
proximately 7 %. MRI is more accurate and shows microscopic
fat in 35–77 % of cases [45]. Benign nodular steatosis and fat-
containing HCC cannot be completely differentiated from
steatotic HCA on imaging alone andmay need further evaluation
with histopathological and/or immunohistochemical analyses
[46]. HNF1α-mutated HCA is the least aggressive subtype and
has minimal or no risk of malignant transformation. Tumours
<5 cm show minimal risk of bleeding [35].
β-Catenin-mutated HCAs
β-Catenin-mutated HCAs are the third most common subtype
and constitute 10–15 % of all HCAs. These occur more
Fig. 6 A 30-year-old female with incidental detection of a hypoechoic
nodule on ultrasound. (a) Axial fat-saturated T2WMRI shows an iso- to
hyperintense lesion (asterisk) in the left lobe of the liver with a peripheral
T2 hyperintense rim (arrow) representing the atoll sign. Axial T1 in-
phase (b) and out-of-phase (c) MRI shows no drop in signal (arrows).
(d) Axial post-contrast MRI in the arterial phase shows moderate
heterogeneous central enhancement (asterisk) and peripheral rim en-
hancement (arrow). Axial post-contrast MRI in the venous phase (e)
and delayed phases (f) shows persistent enhancement (asterisk) with de-
layed enhancement of the peripheral rim (arrow). Surgical resection con-
firmed the diagnosis of inflammatory hepatocellular adenoma
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frequently in males and are associated with male hormone
administration, glycogen storage disease and familial
adenomatosis polyposis [39]. The incidence of HCAs in gly-
cogen storage disease varies from 22–75 and 75 % of these
patients older than 30 years harbour HCA. Chronic liver in-
flammation due to glycogen storage disease leads to the de-
velopment of HCA and HCC. There is a gain of chromosome
6p and loss of chromosome 6q in these patients, which are
also frequently seen in HCC and dysplastic nodules, thereby
accounting for the high risk of malignant transformation asso-
ciated with HCAs in patients with glycogen storage disease
[47].
β-Catenin is encoded by the catenin β 1 gene
(CTNNB1), located at chromosome 3p21. Mutation re-
sults in sustained activation of β-catenin protein,
resulting in uncontrolled hepatocyte proliferation. Cyto-
logic abnormalities, such as a high nuclear-cytoplasmic
ratio, nuclear atypia and acini formation, are seen on
histopathology and mimic well-differentiated hepatocel-
lular carcinoma. Strong and diffuse positivity to gluta-
mine synthase is characteristic of this subtype on immu-
nohistochemical analysis [36].
On MRI, these tumours show heterogeneous T2 sig-
nal, which can be iso-, hypo- or hyperintense relative to
the liver and shows no intratumoral steatosis. Intense
arterial enhancement is seen, which may or may not
persist into the delayed phase. Portal venous washout
can be seen mimicking HCC [2]. A recent study corre-
lates the presence of a vaguely demarcated scar and
poorly delimited high-signal-intensity areas on T2-
weighted images to β-catenin positivity [42] (Fig. 9).
Tumours occurring in the setting of glycogen storage
disease may show diffuse increased attenuation of liver
on CT images.
Fig. 7 A 38-year-old female with multiple liver lesions. This morbidly
obese patient presented with acute abdominal pain and a solitary liver
lesion in the lateral segment (white arrow) detected on axial contrast-
enhanced CT (a).Peri-lesional complex fluid was noted (not shown)
and the patient was taken to the operative theatre where a haemorrhagic
liver lesion was resected. Four other liver lesions were noted at the time of
surgery. The clinical and operative presumptive diagnosis was multiple
hepatocellular adenomas, most likely of the inflammatory subtype. The
original histopathological analysis described the resected lesion as an
atypical focal nodular hyperplasia. Immunohistochemistry was per-
formed several months later. Glutaminesynthetase stains depicted typical
perivascular staining consistent with adenoma (not shown). b Catenin
stains were negative and combined with the history of morbid obesity
and metabolic syndrome a diagnosis of inflammatory adenoma was
given. Follow-up MR examination was performed 2 years after surgery.
Axial fat-suppressed T2W FSE images (b and c) demonstrate two lesions
in the lateral segment (white arrow) and in the right anterior lobe
(arrowhead) with increased T2W signal intensity relative to the liver.
There is a faint peripheral rim of increased signal in the lateral segment
lesion consistent with an atoll sign. Axial T1W images in (d) and opposed
(e) phase demonstrate moderate diffuse hepatic steatosis and
inhomogeneous intralesional steatosis(note the peripheral signal intensity
drop) within both lesions (arrows). Also note the susceptibility artefact on
the in-phase GRE image (d) at the lateral margin of the left lobe related to
previous resection. Axial fat-suppressed T1WGRE images obtained after
injection of extracellular gadolinium during the hepatic arterial (f), portal
venous (g) and 5-min delayed (h) phases depict heterogeneous arterial
enhancement that persists on delayed phases (arrows)
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Unclassified HCAs
This subtype constitutes approximately 10 % and does not
show HNF1 a, CTNNB1 or IL6ST mutations. The predomi-
nant molecular pathogenesis and clinical and radiological fea-
tures of this subset of tumours are poorly understood and
further research is warranted [40].
Hepatic adenomatosis
Hepatic adenomatosis has been defined as the presence of
multiple adenomas (arbitrarily >10) without any history of
steroid therapy or glycogen storage disease [48]. It occurs in
females during the 4th and 5th decades of life. Proposed aeti-
ologies include congenital or acquired hepatic vascular
Fig. 8 A 26-year-old female with right upper quadrant pain was found to
have an echogenic nodule on ultrasound. (a) Axial T2W MRI shows an
isointense lesion in the left lobe of the liver (arrow). Axial T1 in-phase (b)
and out-of-phase (c) MRIs show a drop in signal in the out-of-phase
images representing intralesional lipids (arrow). Axial post-contrast
MRI in the arterial phase (d) shows mild diffuse enhancement of the
lesion (arrow), not persisting in the portal venous (e) and delayed phases
(f). MRI features are consistent with HNF-1α-mutated hepatocellular
adenoma and the patient is on regular follow-up
Fig. 9 A 42-year-old female with incidental detection of liver nodule. (a)
Axial T2WMRI shows a small ill-defined lesion in segment 6 with vague
T2 hyperintense areas. Axial T1 in-phase (b) and out-of-phase (c) MRIs
show a drop in signal around the lesion indicating perilesional steatosis.
Axial post-contrast MRI shows moderate enhancement (arrows) in the
arterial phase (d) becoming iso- to mildly hypointense on delayed phase
(e). Ultrasound-guided biopsy revealed hepatocellular adenoma (immu-
nohistochemistry and genetic analysis not performed). Follow-up MRI
after 2 years showed significant interval growth (short arrow) with vague
T2 hyperintense areas (long arrow) on axial T2W MRI (f). Axial post-
contrast MRI shows moderate heterogeneous enhancement (arrow) in the
arterial phase (g) becoming iso- to mildly hypointense on delayed phase
(e) with mild delayed enhancement of a vague central scar (long arrow).
Surgical resection showed hepatocellular adenoma with multiple foci of
well-differentiated hepatocellular carcinoma and genetic analysis re-
vealed β-catenin mutation
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abnormalities, mutations of the HNF1A gene and non-
alcoholic fatty liver disease. HCAs in patients with hepatic
adenomatosis may be of the inflammatory, HNF-1a-mutated
orβ-catenin-mutated subtypes, and their imaging appearances
may vary accordingly [49] (Fig. 10). Contrary to the popular
belief of increased complications in hepatic adenomatosis, a
recent meta-analysis showed that hepatic adenomatosis per se
does not have any increased risk of complications; the tumour
size and subtype determine the risks of malignancy and bleed-
ing [50]. Associated MODY should be evaluated in patients
with hepatic adenomatosis and liver imaging is recommended
in the relatives [51].
Role of hepatobiliary-specific contrast
The appearance of FNH on hepatobiliary contrast has been
discussed previously in the article. As FNH is a do-not-
touch lesion and HCAs often warrant surgery, differentiating
both of them, also from malignant hepatic lesions, is of prime
importance. Hepatobiliary contrast is now being increasingly
used in atypical cases for differentiation, thereby avoiding
invasive biopsies in a good number of cases.
HCAs showmild-to-moderate arterial enhancement in con-
trast to intense enhancement in FNH. However the inflamma-
tory subtype can show arterial enhancement similar to FNH.
The majority of HCAs (93 %) become hypointense on portal
venous and delayed hepatobiliary phases with gadoxetic acid,
unlike FNH (Fig. 11). The absence of biliary ducts in adeno-
mas, and therefore reduced biliary excretion mechanisms, is
believed to be one of the factors responsible for the decreased
uptake. Again the inflammatory subtype can show mild
hyperintensity on hepatobiliary phase possibly due to pooling
of the contrast agent within the peliotic areas [18, 52]. Perhaps
the most important recent discovery regarding inflammatory
HCA is that it can mimic FNH on MRI. Thomeer et al. and
Agarwal et al. both identified that 25 and 46 % of inflamma-
tory HCAs are iso-hyperintense on the hepatobiliary phase on
gadoxetic acid-enhanced MRI [53, 54]. In addition, they often
mimicked FNH on other imaging sequences. These two recent
publications should caution radiologists when using
hepatocyte-specific contrast agents to diagnose FNH; if pa-
tients are at high risk for the inflammatory type of HCA (obe-
sity, alcohol use), it may not be appropriate to rely on imaging
features alone to make a diagnosis of FNH.
Complications
The two major complications of HCAs are (a) intratumoral
bleeding with or without associated rupture and
haemoperitoneum and (b) malignant transformation to
Fig. 10 Hepatic adenomatosis in a 45-year-old male. (a), (b) and (c)
Axial T2WMRI at multiple levels shows at least three mildly T2 hyper-
intense focal lesions (long arrows) in the right and left lobes of the liver
with vague central T2 hyperintense areas (short arrows). (d) and (e) Axial
post-contrast MRI in the arterial phase shows moderate enhancement of
the lesions (long arrows) with central non-enhancing areas (short
arrows). (f) Axial post-contrast MRI in the delayed phase shows no
persistent enhancement with mild delayed enhancement of central areas
(short arrows). Ultrasound-guided biopsy showed β-catenin-mutated he-
patocellular adenoma with no dysplasia. The patient is planned for liver
transplantation
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HCC. Different subtypes of HCA show variable complica-
tion rates.
Haemorrhage can occur in 15–20 % of HCAs [55]. Bleed-
ing can be intratumoral, intrahepatic or extrahepatic (Fig. 12).
Fig. 11 A 43-year-old female with typical hepatocyte nuclear factor 1al-
pha (HNF-1alpha)-inactivated hepatocellular adenoma. Axial
T2W HASTE image (a) demonstrates a well-circumscribed mass in the
lateral segment, which is only minimally hyperintense to the adjacent
liver parenchyma (white arrow). There is a focal region of more increased
T2W signal centrally (arrowhead). Axial in (b) and opposed (c) phase
T1W dual echo GRE images demonstrate homogeneous loss of signal
intensity within the lesion (white arrows) but no SI drop in the adjacent
liver. Note misregistration between (b) and (c) as images were acquired in
separate breath-holds. Axial fat-suppressed T1W GRE images after the
injection of gadoxetic acid during the early arterial (d), portal venous (e)
and 20-min hepatobiliary (f) phases demonstrate heterogeneous arterial
enhancement with lack of persistent enhancement on portal venous phase
and no uptake of gadoxetic acid during the hepatobiliary phase (arrows)
Fig. 12 Hepatocellular adenoma with haemorrhage in a 40-year-
old female on oral contraceptive pills. (a) Large heterogeneous
lesion involving segment 8 and 4 of the liver showing a well-
defined T2 hyperintense area along its medial aspect (long arrow)
and T2 isointense area along its lateral aspect (short arrow). Axial
T1 in-phase (b) and out-of-phase (c) MRI shows heterogeneous
T1 hyperintensity in the medial portion (long arrow) without
signal drop representing subacute haemorrhage. Axial post-
contrast MRI shows heterogeneous mild-to-moderate enhancement
of the lateral part of the lesion (short arrow) in the arterial phase
(d) becoming isointense on venous (e) and delayed phases (f).
The haemorrhagic component in the medial part of the lesion
(long arrow) shows only peripheral capsular enhancement
(arrowhead)
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Risk factors for bleeding of HCA include a diameter of 35mm
or more, visualisation of central and peripheral intralesional
arteries, location in the left lateral liver and exophytic growth
[56]. Although peliosis is much more common in the inflam-
matory subtype compared to the HNF 1-alpha subtypes (52 %
vs. 4 %), there is no notable difference in the risk of clinically
manifest bleeding between these two subtypes (16 % vs. 9 %)
[33]. Bleeding is very rare in the β-catenin subtype although
the exact incidence is unknown.
Malignant transformation of hepatic adenoma to hepatocel-
lular carcinoma has been variably reported to occur in 5–10%,
and a recent meta-analysis showed the risk of malignant trans-
formation to be 4% in females and 47% inmales [57, 58]. The
important risk factors for malignant transformation of HCAs
are male sex, obesity, concomitant glycogen storage disease,
anabolic steroid usage, β-catenin–mutated subtype and tu-
mours larger than 5 cm in maximum dimension. β-Catenin-
mutated HCAs show the highest risk of malignancy among all
the subtypes. Two-thirds of HCAs with malignant transforma-
tion show β-catenin mutation and one-third display cell
atypias. Also metabolic syndrome is an emerging condition
and has been associated with malignant transformation of
HCA in males [57]. Hepatocellular carcinomas may develop
either as a macroscopic nodule larger than 1 cm in maximum
dimension or as multiple microscopic foci. Approximately
10 % of the inflammatory subtype can show additional β-
catenin activation and may progress to HCC [36].
Management
Recent classification of HCAs into different subtypes has
allowed better understanding of the natural history and bio-
logical behaviour of these relatively rare tumours. This has
great implications for the imaging and management of these
tumours.Many of the previously followed treatment strategies
such as surgical resection for all hepatic adenomas and liver
transplantation for multiple adenomas are now changing as we
have better insight into these tumours because of recent ad-
vances in molecular genetics and imaging [35]. Early recom-
mendations onmanagement were made by Bioulac-Sage et al.
based on the clinical features, gender, molecular subtype and
imaging features [39].
Fig. 13 The algorithmic approach to the management of hepatocellular adenoma (HCA) based on clinical features, gender, imaging and histology
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The management strategy is broadly based on the presence or
absence of symptoms (Fig. 13). Incidental depiction of hepatic
adenoma in an asymptomatic patient needs subtype classification
based on MRI as steatotic (corresponding to HNF 1-alpha) and
heterogeneous non-steatotic (inflammatory, β-catenin and
unclassifiied) hepatic adenomas. Steatotic HCAs have no signif-
icant malignant risk; the risk of bleeding is low and hence can be
managed by clinical and imaging follow-up without resection or
need of biopsy. Heterogeneous non-steatotic HCAs larger than
5 cm, HCAs that continue to grow after stopping use of the
offending drugs, HCAs with β-catenin activation, HCAs with
malignant changes and all HCAs in males need surgical resec-
tion. Resection is effective, with low rates of recurrence [36, 39].
Biopsy is recommended for non-steatotic HCAs less than 5 cm
to look for β-catenin mutation, which has a high risk of malig-
nant transformation and needs resection.
In symptomatic HCAs treatment depends on the duration and
type of symptoms. Patients who are haemodynamically unstable
because of intra- or extrahepatic bleeding require immediate
treatment with either hepatic artery embolisation or surgery
[59]. Conservative treatment may be considered in haemody-
namically stable patients followed by elective definite manage-
ment, which can be surgery, chemoembolisation or RFA. Trans-
arterial chemoembolisation reduces the risk of bleeding during
elective surgery andmay avoid surgical resection. Radiofrequen-
cy ablation is an effective, less invasive approach for (1) tumours
smaller than 4 cm in maximum dimension, (2) patients who are
not surgical candidates and (3) those who prefer to avoid surgery
after discussion and full understanding of the available treatment
options. Radiofrequency ablation has been found to be the most
cost-effective approach in the management of small HCAs as
compared with surgery, transarterial embolisation and watchful
waiting [60].
There are no established guidelines on the optimal interval
and duration of follow-up. Yearly imaging surveillance of
HCAs is recommended for both solitary HCA and hepatic
adenomatosis, and some authors recommend periodic surveil-
lance until menopause [40].
Management of hepatic adenomatosis should depend on
the underlying histological subtype and size of the lesions
rather than on their number. Symptomatic lesions and asymp-
tomatic lesions larger than 5 cm require surgical resection.
Liver transplantation is recommended if there is progressive
liver failure or malignant transformation and is no longer ad-
vised for patients with asymptomatic familial adenomatosis
[61]. Genetic counselling for MODY3 is recommended.Man-
agement of HCAs in patients of child-bearing age is compli-
cated because of the possible increased risk of bleeding and
growth during pregnancy. Overall treatment strategies are sim-
ilar to those in non-pregnant females; however close clinical
and imaging monitoring is recommended for early detection
of complications that may need aggressive management be-
cause of increased foeto-maternal morbidity [62].
Conclusion
Recent advances in the molecular genetics and genotype-
phenotype correlations in benign hepatocellular tumours have
greatly improved our understanding leading to subtype
Table 2 Summary of MRI features of major subtypes of hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH)
Subtype T1W T2W In and out
of phase
Arterial Portal venous/delayed Remarks
Focal nodular
hyperplasia
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Intense Variable. May show
portal venous
washout
Faint scar and ill-
defined T2 hyper-
intense foci
Unclassified – – – – –
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recognit ion and better differentiation from other
hypervascular lesions. Each of these tumour subtypes has dis-
tinct genetic mutations, molecular abnormalities, histopatho-
logical features, imaging findings, biological behaviour and
prognosis. FNH typically does not bleed or undergomalignant
change. HCAs with β-catenin mutations frequently undergo
malignant change, inflammatory HCAs commonly bleed, and
HNF-1α HCAs typically show a favourable prognosis. Many
of these have reasonably specific imaging features permitting
accurate diagnosis, which has significant implications for their
management (Tables 1 and 2).
Open Access This article is distributed under the terms of the Creative
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